leisure time -WSS

leisure time

author：entertainment 2025-10-02 15:43:26 - browse：9

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： New safety details link Apellis eye drug to rare cases of blindness

WSS

Eli Lilly expects to double planned employment in Boston center

Medicare reduced heart disease by changing how it pays doctors

Physician groups backed by private equity giant lobby on mergers

NIH confirmation hearing shows politicization of research

Solve the antibiotic resistance crisis with preventive drugs

Trump indictment: Who are the 'co

hotspot

leisure time

Wikipedia

Medical leaders decry Supreme Court decision on affirmative action

Why health workers in Gaza are injured or die at high rates

What does generative AI mean for health care? We asked experts

UnitedHealth’s board chair also owns a personal investment firm

Peter Hotez and the public health issue of online harassment

STAT Summit: Biotech founders on deal

Medicare proposal to cover medical devices draws a mixed reaction

Vertex non

23andMe had bad news about my health. I wish a person had delivered it

Pharmacists can make shortage drugs, but at what cost?

knowledge

Sage hopes for a blockbuster in antidepressant now before FDA

Pharmacists can make shortage drugs, but at what cost?

Why health workers in Gaza are injured or die at high rates

Mega Millions pot grows to $1.25 billion after no winner

Researchers explore possible ties between long Covid, menopause

Studies point to risks of excluding people with obesity from drug trials

hotspot

entertainment

explore

Wikipedia